Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer

NCT03258398 is registered in ClinicalTrials.gov with Effector Therapeutics as lead sponsor.

NCT NCT03258398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03258398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Lead sponsor
Effector Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 18, 2017
Completion date
May 13, 2019
Enrollment
56 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

microsatellite stable relapsed or refractory colorectal cancer